CAPR logo

CAPR
Capricor Therapeutics Inc

30,024
Mkt Cap
$1.22B
Volume
1.04M
52W High
$40.37
52W Low
$4.30
PE Ratio
-12.48
CAPR Fundamentals
Price
$22.45
Prev Close
$23.67
Open
$24.24
50D MA
$25.71
Beta
1.11
Avg. Volume
1.37M
EPS (Annual)
-$1.15
P/B
12.24
Rev/Employee
$139,190.41
$339.33
Loading...
Loading...
News
all
press releases
Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Above 50-Day Moving Average - Time to Sell?
Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above Fifty Day Moving Average - Time to Sell...
MarketBeat·9d ago
News Placeholder
More News
News Placeholder
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Rating of "Moderate Buy" from Analysts
Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the ten ratings firms that are covering the firm, Marketbeat...
MarketBeat·17d ago
News Placeholder
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.7% - Here's Why
Capricor Therapeutics (NASDAQ:CAPR) Trading Down 6.7% - Should You Sell...
MarketBeat·18d ago
News Placeholder
CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February
CAPR said the FDA wants the full HOPE-3 study report for Deramiocel and confirmed no new clinical trials are needed.
Zacks·25d ago
News Placeholder
CAPR Stock Slides After FDA Requests More Data For Genetic Disorder Therapy — What Does Retail Think?
The FDA has formally requested the full HOPE-3 clinical study report (CSR) and supporting data, Capricor said on Tuesday.
Stocktwits·26d ago
News Placeholder
Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above 50 Day Moving Average - Here's Why
Capricor Therapeutics (NASDAQ:CAPR) Share Price Crosses Above 50-Day Moving Average - Time to Sell...
MarketBeat·27d ago
News Placeholder
Capricor Therapeutics (NASDAQ:CAPR) Cut to Sell at Wall Street Zen
Wall Street Zen lowered Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday...
MarketBeat·1mo ago
News Placeholder
Capricor Therapeutics (NASDAQ:CAPR) Shares Down 7.8% - What's Next?
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 7.8% - Here's Why...
MarketBeat·1mo ago
News Placeholder
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Recommendation of "Moderate Buy" from Analysts
Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the ten research firms that are currently covering the firm, MarketBeat...
MarketBeat·1mo ago
News Placeholder
Capricor Therapeutics (NASDAQ:CAPR) Upgraded at Wall Street Zen
Wall Street Zen raised Capricor Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·1mo ago
<
1
2
...
>

Latest CAPR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.